Surveillance of low-grade appendiceal mucinous neoplasms for progression to pseudomyxoma peritonei: Results from a

Enda Hannan1, Lorena Martin Roman1, Lukas O'Brien1

  • 1The National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Dublin, Ireland.

Abstract

Insights

Surveillance after appendiceal mucinous neoplasm resection is crucial, as 6% of patients progressed to pseudomyxoma peritonei within 3 years. Early detection of subclinical progression is possible with structured monitoring.

Area of Science:

  • Gastroenterology
  • Surgical Oncology
  • Oncology

Background:

  • Low-grade appendiceal mucinous neoplasm (LAMN) is a rare appendix tumor with potential to progress to pseudomyxoma peritonei (PMP).
  • Standardized surveillance protocols post-LAMN resection are lacking due to unclear progression rates.
  • This study aimed to determine LAMN progression to PMP in a structured surveillance program.

Purpose of the Study:

  • To evaluate the rate of progression from LAMN to PMP following surgical resection.
  • To identify risk factors associated with disease progression.
  • To assess the effectiveness of a structured surveillance program for early PMP detection.

Main Methods:

  • Retrospective collection of data for patients undergoing LAMN surveillance from 2013 to 2021.
  • Surveillance protocol included annual CT scans and tumor marker assessments for 5 years.
  • Identification of patients who progressed to PMP during the follow-up period.

Main Results:

  • Of 83 patients completing at least one year of surveillance, 6% (n=5) progressed to PMP.
  • Median time to progression was 23 months, with highest risk within the first 3 years.
  • Progression was significantly associated with M1b staging (p=0.021) and extratumoral mucin (p=0.04), but not T staging, margin status, or perforation.

Conclusions:

  • The observed progression rate supports the necessity of post-appendicectomy surveillance for LAMN patients.
  • The risk of progression to PMP is highest within the first three years post-diagnosis.
  • The structured surveillance program facilitates early detection of subclinical PMP progression.